FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Manuel Hidalgo

Research Profile

Chemicals & Drugs

Disorders

Procedures

Living Beings

Anatomy

Tumor Cell Line

Physiology

Concepts & Ideas

Co-author Network

Publications

TOP 3
Nilofer S Azad; Michael A Carducci; Arvind Dasari; Luis Alberto Diaz; Ross C Donehower; Manuel Hidalgo; Daniel Laheru; Martine McManus; Kevin Quackenbush; MICHELLE RUDEK-RENAUT; Gretchen E Taylor; John J Wright; Ming Zhao; John Arcaroli; Wells A Messersmith
Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer.
Esther Conde; Nuria Dominguez; Manuel Hidalgo; Elisa Izquierdo; Luis Madrigal; Luna Muñoz; Carlos Plaza; Belen Rubio-Viqueira; Ana Suárez-Gauthier; Maribel Torres; Bárbara Angulo; Cristóbal Belda-Iniesta; Fernando López-Ríos
The ALK translocation in advanced non-small-cell lung carcinomas: preapproval testing experience at a single cancer centre.
Hirohiko Kamiyama; Mihoko Kamiyama; Balasubramanyam Karanam; Collins A Karikari; Hong Liang; Ming-Tseh Lin; Jun O Liu; Anirban Maitra; Guanglan Mo; Michael Mullendore; Sherri Rauenzahn; Richard B S Roden; F William Schuler; Joong Sup Shim; Georg Feldmann; Manuel Hidalgo; Ralph Hruban; Li Hua; Elizabeth Jaffee; Antonio Jimeno; H A Jinnah; Robert M Beaty; James R Eshleman
Personalized chemotherapy profiling using cancer cell lines from selectable mice.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Manuel Hidalgo (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Nilofer S Azad; Michael A Carducci; Arvind Dasari; Luis Alberto Diaz; Ross C Donehower; Manuel Hidalgo; Daniel Laheru; Martine McManus; Kevin Quackenbush; MICHELLE RUDEK-RENAUT; Gretchen E Taylor; John J Wright; Ming Zhao; John Arcaroli; Wells A Messersmith
Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer.
Investigational new drugs 2013;31(2):345-54.
2013: Esther Conde; Nuria Dominguez; Manuel Hidalgo; Elisa Izquierdo; Luis Madrigal; Luna Muñoz; Carlos Plaza; Belen Rubio-Viqueira; Ana Suárez-Gauthier; Maribel Torres; Bárbara Angulo; Cristóbal Belda-Iniesta; Fernando López-Ríos
The ALK translocation in advanced non-small-cell lung carcinomas: preapproval testing experience at a single cancer centre.
Histopathology 2013;62(4):609-16.
2013: Hirohiko Kamiyama; Mihoko Kamiyama; Balasubramanyam Karanam; Collins A Karikari; Hong Liang; Ming-Tseh Lin; Jun O Liu; Anirban Maitra; Guanglan Mo; Michael Mullendore; Sherri Rauenzahn; Richard B S Roden; F William Schuler; Joong Sup Shim; Georg Feldmann; Manuel Hidalgo; Ralph Hruban; Li Hua; Elizabeth Jaffee; Antonio Jimeno; H A Jinnah; Robert M Beaty; James R Eshleman
Personalized chemotherapy profiling using cancer cell lines from selectable mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 2013;19(5):1139-46.
2013: J Rodríguez-Pascual; P Sha; Yolanda Quijano; N V Rajeshkumar; B Angulo; A Cubillo; Emilio de Vicente; Elena García-García; O Hernando; Manuel Hidalgo
A preclinical and clinical study of mycophenolate mofetil in pancreatic cancer.
Investigational new drugs 2013;31(1):14-9.
2012: Daniel Laheru; DUNG LE; Sheila Linden; Florencia McAllister; RAJESH KUMAR NV; MICHELLE RUDEK-RENAUT; Preeti Shah; Dongweon Song; Gretchen Taylor; Ming Zhao; Ross C Donehower; Howard Goldsweig; Antonio Jimeno; Manuel Hidalgo
Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer.
Investigational new drugs 2012;30(6):2391-9.
2012: Glen J Weiss; Lisa Blaydorn; Mitesh J Borad; Marina Ciomei; francesco Fiorentini; Manuel Hidalgo; Jeffrey D Isaacs; Gayle Jameson; Antonio Jimeno; Daniel Laheru; Maria Adele Pacciarini; Ramesh K Ramanathan; Angela Scaburri; Raoul Tibes; Daniel D Von Hoff
Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies.
Investigational new drugs 2012;30(6):2334-43.
2012: John Arcaroli; Arvind Dasari; Charles Erlichman; Nathan R Foster; Manuel Hidalgo; Martine McManus; Sujatha Nallapareddy; Joel Picus; Rebecca Powell; Kevin Quackenbush; Aik Choon Tan; John Wright; Wells A Messersmith
Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer.
Cancer medicine 2012;1(2):207-17.
2012: Manuel Hidalgo
New insights into pancreatic cancer biology.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012;23 Suppl 10():x135-8.
2012: Masamichi Mizuma; Noriyuki Omura; Oscar Puig; Nathaniel R Campbell; Elizabeth De Oliveira; Roeland F de Wilde; Manuel Hidalgo; Anirban Maitra; William Matsui; Zeshaan A Rasheed; Shinichi Yabuuchi; Qing Zhang; RAJESH KUMAR NV
The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models.
Molecular cancer therapeutics 2012;11(9):1999-2009.
2012: Manuel Hidalgo; Daniel D Von Hoff
Translational therapeutic opportunities in ductal adenocarcinoma of the pancreas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(16):4249-56.
2012: Colin D Weekes; Lora A Wilson; Robert A Winn; Wells A Messersmith; Belen Rubio-Viqueira; Dongweon Song; John Arcaroli; George Cusatis; Elizabeth Garrett-Mayer; Manuel Hidalgo
Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer.
Neoplasia (New York, N.Y.) 2012;14(8):690-701.
2012: Carlos Gómez-Martin; Manuel Hidalgo; José Luis Rodríguez-Peralto; Alberto Arcediano; Anabel Ballesteros; M José Echarri; Elena Garralda; Fernando López-Ríos
HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer.
Journal of clinical pathology 2012;65(8):751-7.
2012: Isabel Ruppen-Cañás; Antonio Serna; Pilar Ximénez-Embún; Fernando García; Manuel Hidalgo; Pedro P López-Casas; M Pia Morelli; Manuel Muñoz; Francisco X Real; Keith Ashman
An improved quantitative mass spectrometry analysis of tumor specific mutant proteins at high sensitivity.
Proteomics 2012;12(9):1319-27.
2012: M Pia Morelli; Sujatha Nallapareddy; Todd M Pitts; Natalie J Serkova; Aik Choon Tan; John J Tentler; John J Arcaroli; Erica L Bradshaw-Pierce; Amy M Brown; Fortunato Ciardiello; Manuel Hidalgo; Gillian N Kulikowski; S Gail Eckhardt
Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(4):1051-62.
2012: M Pia Morelli; Esther Ordoñez; David Sidransky; Belen-Rubio Viqueira; Michael J Wick; Elizabeth Bruckheimer; Antonio Calles-Blanco; Emiliano Calvo; Pedro P Lopez-Casas; Manuel Hidalgo
Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(4):e45-8.
2012: Agustin F Fernandez; Isidre Ferrer; Mario F Fraga; Oliver Galm; Osvaldo Graña; Manuel Hidalgo; Thomas Lengauer; Ramon Martinez; Jose Ignacio Martin-Subero; Meltzer Stephen J.; David Monk; Jaume Mora; Victor Moreno; Luis Perez-Jurado; Jaime Prat; Felipe Prosper; Annibale A Puca; Susana Puig; Santiago Ropero; Marta Sanchez-Carbayo; Montse Sanchez-Cespedes; Jose V Sanchez-Mut; Reiner Siebert; Aik-Choon Tan; Hiroaki Taniguchi; Alberto Villanueva; Hiroyuki Yamamoto; Xabier Agirre; Yassen Assenov; Lina Badimon; Balazs Balint; Esteban Ballestar; Maria Berdasco; Christoph Bock; John Bridgewater; Gabriel Capella; Javier Carmona; Manel Esteller
A DNA methylation fingerprint of 1628 human samples.
Genome research 2012;22(2):407-19.
2012: A Hunter Shain; Murali D Bashyam; Craig P Giacomini; Manuel Hidalgo; Collins A Karikari; Anirban Maitra; Karen Matsukuma; Jonathan R Pollack
Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer.
Proceedings of the National Academy of Sciences of the United States of America 2012;109(5):E252-9.
2012: Bárbara Angulo; Esther Conde; Manuel Hidalgo; Elisa Izquierdo; Rebeca Martínez; Luis Paz-Ares; Carlos Plaza; Pilar Redondo; Belen Rubio-Viqueira; Ana Suárez-Gauthier; Fernando López-Ríos
A comparison of EGFR mutation testing methods in lung carcinoma: direct sequencing, real-time PCR and immunohistochemistry.
PloS one 2012;7(8):e43842.
2012: Javier Sastre; Manuel Valladares-Ayerbes; Manuel Benavides; Eduardo Díaz-Rubio; Cristina Grávalos; Manuel Hidalgo; José L Manzano; Eugenio Marcuello; Bartomeu Massuti; Fernando Rivera; Enrique Aranda
First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study.
The oncologist 2012;17(3):339-45.
2012: Manuel Hidalgo
From node to pathway blockade: lessons learned from targeting mammalian target of rapamycin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(1):85-7.
2011: Matilde Murga; Thomas Schleker; Rebeca Soria; Luis I Toledo; Bruno Amati; Mariano Barbacid; Stefano Campaner; Luana D'Artista; Elena Garcia; Carmen Guerra; Manuel Hidalgo; Andres J Lopez-Contreras; Maria F Montaña; Oscar Fernandez-Capetillo
Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors.
Nature structural & molecular biology 2011;18(12):1331-5.
2011: Daniel D Von Hoff; Tina E Wood; Hui Zhang; Mitesh J Borad; Neil Desai; Jose L Iglesias; Ronald L Korn; Daniel Laheru; Anirban Maitra; N V Rajeshkumar; Ramesh K Ramanathan; Tao Shi; Lon S Smith; Patrick Soon-Shiong; Vuong Trieu; Manuel Hidalgo
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(34):4548-54.
2011: Enza Lonardo; Irene Miranda-Lorenzo; Maria-Theresa Mueller; Juan Carlos Ramirez; Iker Rodriguez-Arabaolaza; Raul Torres-Ruíz; Sladjana Zagorac; Patrick C Hermann; Rainer Heuchel; Manuel Hidalgo; Stephan Huber; Matthias Löhr; Alexandra Aicher; Sonia Alcala; Anamaria Balic; Peter Bartenstein; Frank Berger; David Álvaro Cebrián; Elena Garcia; Christopher Heeschen
Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy.
Cell stem cell 2011;9(5):433-46.
2011: José Perea; Yolanda Rodríguez; Daniel Rueda; Edurne Álvaro; Cristina Alegre; Javier Benítez; Francisco Colina; José Díaz-Tasende; Manuel Hidalgo; Manuel Lomas; JC Marín; Irene Osorio; Miguel Urioste
Early-onset colorectal cancer is an easy and effective tool to identify retrospectively Lynch syndrome.
Annals of surgical oncology 2011;18(12):3285-91.
2011: Irene Osorio; Manuel Hidalgo; Manuel Lomas; José Perea
[Surgical management of familial colorectal cancer type X].
Cirugía española 2011;89(9):620-2.
2011: Georg Feldmann; Volker Fendrich; Ignacio Garrido-Laguna; Manuel Hidalgo; Collins A Karikari; Anirban Maitra; William Matsui; Anjali Mishra; Hector Alvarez; Rajat Bannerji; Savita Bisht; Peter Brossart; Tikva Dadon; Niki A Ottenhof; RAJESH KUMAR NV; Zeshaan A Rasheed; Barry D Nelkin
Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models.
Cancer biology & therapy 2011;12(7):598-609.
2011: Colin D Weekes; Sharyn D Baker; Ross C Donehower; Manuel Hidalgo; Antonio Jimeno; Daniel Laheru; KATHLEEN MURPHY; Sujatha Nallapareddy; Alexis Norris-Kirby; MICHELLE RUDEK-RENAUT; Wells A Messersmith
Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer.
Investigational new drugs 2011;29(5):1057-65.
2011: Manuel Hidalgo; José Perea; Eduardo Ferrero; Ana Hidalgo
Liver hydatidosis in the present decade.
Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva 2011;103(9):445-7.
2011: Ignacio Garrido-Laguna; Manuel Hidalgo; Razelle Kurzrock
The inverted pyramid of biomarker-driven trials.
Nature reviews. Clinical oncology 2011;8(9):562-6.
2011: Ignacio Garrido-Laguna; Elizabeth de Oliveira; Ralph Hruban; Antonio Jimeno; Collins A Karikari; Daniel Laheru; Anirban Maitra; RAJESH KUMAR NV; Belen Rubio-Viqueira; Ana Salomon; Rajni Sharma; Aik Choon Tan; Gretchen Taylor; Maria Uson; Maria C Villaroel; Manuel Hidalgo
Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(17):5793-800.
2011: Carlos Gómez-Martín; Manuel Hidalgo; Josep Tabernero; Dolores Isla
SEOM clinical guidelines for the treatment of pancreatic cancer.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2011;13(8):528-35.
2011: Manuel Hidalgo; James Martell; RAJESH KUMAR NV; Belen Rubio-Viqueira; Elizabeth M Bruckheimer; Elizabeth De Oliveira; Ignacio Garrido-Laguna; Steven Strawn; Michael J Wick; David Sidransky
A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer.
Molecular cancer therapeutics 2011;10(8):1311-6.
2011: Elena García-García; Carlos Gómez-Martín; Manuel Hidalgo; Magdalena Adrados; Bárbara Angulo; Esther Conde; Cristian Perna; José Luis Rodríguez-Peralto; Ana Suárez-Gauthier; Fernando López-Ríos
Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method.
Histopathology 2011;59(1):8-17.
2011: N V Rajeshkumar; Stuart D Shumway; James Watters; David Brooks; Elizabeth De Oliveira; Tim Demuth; Hiroshi Hirai; Anirban Maitra; Shinji Mizuarai; Niki Ottenhof; Manuel Hidalgo
MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(9):2799-806.
2011: Eike Gallmeier; Patrick C Hermann; Maria-Theresa Mueller; Juan G Machado; Andreas Ziesch; Enrico N De Toni; Andreas Palagyi; Christian Eisen; Joachim W Ellwart; Jose Rivera; Belen Rubio-Viqueira; Manuel Hidalgo; Fred Bunz; Burkhard Göke; Christopher Heeschen
Inhibition of ataxia telangiectasia- and Rad3-related function abrogates the in vitro and in vivo tumorigenicity of human colon cancer cells through depletion of the CD133(+) tumor-initiating cell fraction.
Stem cells (Dayton, Ohio) 2011;29(3):418-29.
2011: Kevin A Kwei; Anirban Maitra; Kelli Montgomery; Ryan Bair; Murali D Bashyam; Manuel Hidalgo; Collins A Karikari; A Hunter Shain; Matt van de Rijn; Jonathan R Pollack
SMURF1 amplification promotes invasiveness in pancreatic cancer.
PloS one 2011;6(8):e23924.
2011: J Perea; M Lomas; Manuel Hidalgo
Molecular basis of colorrectal cancer: towards an individualized management?
Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva 2011;103(1):29-35.
2011: Maria C Villarroel; N V Rajeshkumar; Ignacio Garrido-Laguna; Ana De Jesus-Acosta; Siân Jones; Anirban Maitra; Ralph Hruban; James R Eshleman; Alison P Klein; Daniel Laheru; Ross C Donehower; Manuel Hidalgo
Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.
Molecular cancer therapeutics 2011;10(1):3-8.
2011: J Sastre; E Aranda; C Grávalos; B Massutí; M Varella-Garcia; F Rivera; G Soler; A Carrato; J L Manzano; E Díaz-Rubio; Manuel Hidalgo
First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD).
Critical reviews in oncology/hematology 2011;77(1):78-84.
2010: Wells A Messersmith; Antonio Jimeno; Heather A Jacene; Ming Zhao; Piotr Kulesza; Daniel Laheru; Yasmin Kahn; Alexander Spira; Janet Dancey; Christine A Iacobuzio-Donahue; Ross C Donehower; Michael A Carducci; MICHELLE RUDEK-RENAUT; Manuel Hidalgo
Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer.
Clinical colorectal cancer 2010;9(5):297-304.
2010: Edurne Alvaro; José Perea; Manuel Lomas; Miguel Urioste; Manuel Hidalgo
[Influence of age on the surgical treatment of lynch syndrome].
Cirugía española 2010;88(5):338-40.
2010: Kota Ishizawa; Zeshaan A Rasheed; Robert Karisch; Qiuju Wang; Jeanne Kowalski; Erica Susky; Keira Pereira; Christina Karamboulas; Nadeem Moghal; N V Rajeshkumar; Manuel Hidalgo; Ming Tsao; Laurie Ailles; Thomas K Waddell; Anirban Maitra; Benjamin G Neel; William Matsui
Tumor-initiating cells are rare in many human tumors.
Cell stem cell 2010;7(3):279-82.
2010: N V Rajeshkumar; Zeshaan A Rasheed; Elena García-García; Fernando López-Ríos; Kosaku Fujiwara; William Matsui; Manuel Hidalgo
A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.
Molecular cancer therapeutics 2010;9(9):2582-92.
2010: I Garrido-Laguna; Aik Choon Tan; M Uson; M Angenendt; Wen W Ma; M C Villaroel; Ming Zhao; RAJESH KUMAR NV; Antonio Jimeno; Ross C Donehower; Christine A Iacobuzio-Donahue; M Barrett; MICHELLE RUDEK-RENAUT; Belen Rubio-Viqueira; Daniel Laheru; Manuel Hidalgo
Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer.
British journal of cancer 2010;103(5):649-55.
2010: Jose Perea; Edurne Alvaro; Yolanda Rodríguez; Cristina Gravalos; Eva Sánchez-Tomé; Barbara Rivera; Francisco Colina; Pablo Carbonell; Rogelio González-Sarmiento; Manuel Hidalgo; Miguel Urioste
Approach to early-onset colorectal cancer: clinicopathological, familial, molecular and immunohistochemical characteristics.
World journal of gastroenterology : WJG 2010;16(29):3697-703.
2010: Rémi Giordanengo; Stéphane Viel; Manuel Hidalgo; Béatrice Allard-Breton; André Thévand; Laurence Charles
Methylation of acidic moieties in poly(methyl methacrylate-co-methacrylic acid) copolymers for end-group characterization by tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM 2010;24(14):1941-7.
2010: Rémi Giordanengo; Stéphane Viel; Manuel Hidalgo; Béatrice Allard-Breton; André Thévand; Laurence Charles
Analytical strategy for the molecular weight determination of random copolymers of poly(methyl methacrylate) and poly(methacrylic acid).
Journal of the American Society for Mass Spectrometry 2010;21(6):1075-85.
2010: Jan C Buckner; Bahram Forouzesh; Charles Erlichman; Manuel Hidalgo; Joseph P Boni; Gary Dukart; Anna Berkenblit; Eric K Rowinsky
Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer.
Investigational new drugs 2010;28(3):334-42.
2010: Bárbara Angulo; Elena García-García; Rebeca Martínez; Ana Suárez-Gauthier; Esther Conde; Manuel Hidalgo; Fernando López-Ríos
A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma.
The Journal of molecular diagnostics : JMD 2010;12(3):292-9.
2010: Manuel Hidalgo
Pancreatic cancer.
The New England journal of medicine 2010;362(17):1605-17.
2010: Zeshaan A Rasheed; Jie Yang; Qiuju Wang; Jeanne Kowalski; Irwin Freed; Christopher Murter; Seung-Mo Hong; Jan-Bart Koorstra; RAJESH KUMAR NV; Xiaobing He; Michael Goggins; Christine A Iacobuzio-Donahue; berman david; Daniel Laheru; Antonio Jimeno; Manuel Hidalgo; Anirban Maitra; William Matsui
Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma.
Journal of the National Cancer Institute 2010;102(5):340-51.
2010: Ming-Tseh Lin; LH Tseng; Hirohiko Kamiyama; Mihoko Kamiyama; Phillip Lim; Manuel Hidalgo; Sarah J Wheelan; James R Eshleman
Quantifying the relative amount of mouse and human DNA in cancer xenografts using species-specific variation in gene length.
BioTechniques 2010;48(3):211-8.
2010: Antonio Jimeno; Belen Rubio-Viqueira; RAJESH KUMAR NV; Audrey Chan; Anna Solomon; Manuel Hidalgo
A fine-needle aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer.
Molecular cancer therapeutics 2010;9(2):311-8.
2010: Wen Wee Ma; JOSEPH HERMAN; Antonio Jimeno; Daniel Laheru; Wells A Messersmith; Christopher L Wolfgang; John L Cameron; Timothy M Pawlik; Ross C Donehower; MICHELLE RUDEK-RENAUT; Manuel Hidalgo
A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer.
Translational oncology 2010;3(6):373-9.
2009: Aik Choon Tan; Antonio Jimeno; Steven H Lin; Jenna Wheelhouse; Fonda Chan; Anna Solomon; RAJESH KUMAR NV; Belen Rubio-Viqueira; Manuel Hidalgo
Characterizing DNA methylation patterns in pancreatic cancer genome.
Molecular oncology 2009;3(5-6):425-38.
2009: Manuel Hidalgo; Anirban Maitra
The hedgehog pathway and pancreatic cancer.
The New England journal of medicine 2009;361(21):2094-6.
2009: Oliver A Kent; Michael Mullendore; Erik A Wentzel; Pedro López-Romero; Aik Choon Tan; Hector Alvarez; Kristen West; Michael Ochs; Manuel Hidalgo; Dan E Arking; Anirban Maitra; Joshua T Mendell
A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells.
Cancer biology & therapy 2009;8(21):2013-24.
2009: Steven L Warner; Bret J Stephens; Stanley Nwokenkwo; Galen Hostetter; Anastasia Sugeng; Manuel Hidalgo; Jeffrey M. Trent; Haiyong Han; Daniel Von Hoff
Validation of TPX2 as a potential therapeutic target in pancreatic cancer cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(21):6519-28.
2009: Maria-Theresa Mueller; Patrick C Hermann; Juliane Witthauer; Belen Rubio-Viqueira; Simon F Leicht; Stephan Huber; Joachim W Ellwart; Mona Mustafa; Peter Bartenstein; Jan G D'Haese; Michael H Schoenberg; Frank Berger; Karl-Walter Jauch; Manuel Hidalgo; Christopher Heeschen
Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer.
Gastroenterology 2009;137(3):1102-13.
2009: Maria Cristina Villarroel; Manuel Hidalgo; Antonio Jimeno
Mycophenolate mofetil: An update.
Drugs of today (Barcelona, Spain : 1998) 2009;45(7):521-32.
2009: RAJESH KUMAR NV; Aik Choon Tan; Elizabeth De Oliveira; Chris Womack; Helen Wombwell; Shethah Morgan; Madhuri V Warren; Jill Walker; Tim P Green; Antonio Jimeno; Wells A Messersmith; Manuel Hidalgo
Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(12):4138-46.
2009: Wells A Messersmith; RAJESH KUMAR NV; Aik Choon Tan; Xiao Fei Wang; Veronica Diesl; Sung E Choe; Max Follettie; Christina Coughlin; Frank Boschelli; Elena Garcia-Garcia; Fernando Lopez-Rios; Antonio Jimeno; Manuel Hidalgo
Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts.
Molecular cancer therapeutics 2009;8(6):1484-93.
2009: Wen Wee Ma; Heather A Jacene; Dongweon Song; Felip Vilardell; Wells A Messersmith; Daniel Laheru; Richard L Wahl; Christopher J Endres; Antonio Jimeno; Martin G Pomper; Manuel Hidalgo
[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(16):2697-704.
2009: Bahram Forouzesh; Manuel Hidalgo; Quincy Chu; Catalin Mita; Monica Mita; Garry Schwartz; José Jimeno; Javier Gómez; Vicente Alfaro; Claudia Lebedinsky; Patrik Zintl; Eric K Rowinsky
Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(10):3591-9.
2009: Manuel Hidalgo; A Abad; E Aranda; L Díez; J Feliu; C Gómez; A Irigoyen; R López; F Rivera; C Rubio; J Sastre; Josep Tabernero; E Díaz-Rubio
Consensus on the treatment of pancreatic cancer in Spain.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2009;11(5):290-301.
2009: Christine A Iacobuzio-Donahue; BAOJIN FU; Shinichi Yachida; Mingde Luo; Hisashi Abe; Clark M Henderson; Felip Vilardell; Zheng Wang; Jesse W Keller; Priya Banerjee; JOSEPH HERMAN; John L Cameron; Charles J Yeo; Marc K Halushka; James R Eshleman; Marian Raben; Alison P Klein; Ralph Hruban; Manuel Hidalgo; Daniel Laheru
DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(11):1806-13.
2009: Shabana Shabbeer; Michelle Sobolewski; RAVI ANCHOORI; Sushant Kachhap; Manuel Hidalgo; Antonio Jimeno; Nancy E Davidson; Michael A Carducci; Saeed R Khan
Fenugreek: a naturally occurring edible spice as an anticancer agent.
Cancer biology & therapy 2009;8(3):272-8.
2009: Antonio Jimeno; Georg Feldmann; Ana Suárez-Gauthier; Zeshaan Rasheed; Anna Solomon; Gang-Ming Zou; Belen Rubio-Viqueira; Elena García-García; Fernando López-Ríos; William Matsui; Anirban Maitra; Manuel Hidalgo
A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development.
Molecular cancer therapeutics 2009;8(2):310-4.
2009: B Rubio-Viqueira; Manuel Hidalgo
Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients.
Clinical pharmacology and therapeutics 2009;85(2):217-21.
2009: A Jimeno; A Chan; George Cusatis; X Zhang; J Wheelhouse; A Solomon; F Chan; Ming Zhao; Stephen Cosenza; M V Ramana Reddy; MICHELLE RUDEK-RENAUT; Piotr Kulesza; Ross C Donehower; E P Reddy; Manuel Hidalgo
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
Oncogene 2009;28(4):610-8.
2009: Jesús Rodríguez-Pascual; Emilio De Vicente; Yolanda Quijano; Francisco Pérez-Rodríguez; Fernando Bergaz; Manuel Hidalgo; Ignacio Duran
Isolated recurrence of distal adenocarcinoma of the extrahepatic bile duct on a draining sinus scar after curative resection: case report and review of the literature.
World journal of surgical oncology 2009;7():96.
2008: Antonio Jimeno; Jing Li; Wells A Messersmith; Daniel Laheru; MICHELLE RUDEK-RENAUT; Manoj Maniar; Manuel Hidalgo; Sharyn D Baker; Ross C Donehower
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(34):5504-10.
2008: Eduardo Ferrero; Maria Labalde; Nuria Fernández; Luis Monge; Adely Salcedo; Raul Narvaez-Sanchez; Manuel Hidalgo; Godofredo Dieguez; Angel Luis García-Villalon
Response to endothelin-1 in arteries from human colorectal tumours: role of endothelin receptors.
Experimental biology and medicine (Maywood, N.J.) 2008;233(12):1602-7.
2008: Wells A Messersmith; Antonio Jimeno; David S Ettinger; Daniel Laheru; Julie R Brahmer; Dina Lansey; Yasmin Khan; Ross C Donehower; Yusri Elsayed; Peter Zannikos; Manuel Hidalgo
Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2008;63(1):181-8.
2008: H C Harsha; Antonio Jimeno; Henrik Molina; Anca B Mihalas; Michael Goggins; Ralph Hruban; Richard D Schulick; Ullas Kamath; Anirban Maitra; Manuel Hidalgo; Akhilesh Pandey
Activated epidermal growth factor receptor as a novel target in pancreatic cancer therapy.
Journal of proteome research 2008;7(11):4651-8.
2008: RAVI ANCHOORI; Madeline Kortenhorst; Manuel Hidalgo; Taradas Sarkar; Gurulingappa Hallur; Ruoli Bai; Paulus van Diest; Ernest Hamel; Saeed R Khan
Novel microtubule-interacting phenoxy pyridine and phenyl sulfanyl pyridine analogues for cancer therapy.
Journal of medicinal chemistry 2008;51(19):5953-7.
2008: Sonsoles Martín-Santamaría; José-Juan Rodríguez; Sonia de Pascual-Teresa; Sandra Gordon; Martin Bengtsson; Ignacio Garrido-Laguna; Belén Rubio-Viqueira; Pedro P López-Casas; Manuel Hidalgo; Beatriz de Pascual-Teresa; Ana Ramos
New scaffolds for the design of selective estrogen receptor modulators.
Organic & biomolecular chemistry 2008;6(19):3486-96.
2008: Dongweon Song; Raghothama Chaerkady; Aik Choon Tan; Elena García-García; Anuradha Nalli; Ana Suárez-Gauthier; Fernando López-Ríos; Xian Feng Zhang; Anna Solomon; Jeffrey Tong; Margaret Read; Christian Fritz; Antonio Jimeno; Akhilesh Pandey; Manuel Hidalgo
Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer.
Molecular cancer therapeutics 2008;7(10):3275-84.
2008: Siân Jones; Xiaosong Zhang; DONALD PARSONS; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; Hirohiko Kamiyama; Antonio Jimeno; Seung-Mo Hong; BAOJIN FU; Ming-Tseh Lin; Eric S Calhoun; Mihoko Kamiyama; Kimberly Walter; Tatiana Nikolskaya; Yuri Nikolsky; James Hartigan; Douglas R Smith; Manuel Hidalgo; Steven D Leach; Alison P Klein; Elizabeth M Jaffee; Michael Goggins; Anirban Maitra; Christine A Iacobuzio-Donahue; James R Eshleman; Scott E Kern; Ralph Hruban; Rachel Karchin; Nickolas Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses.
Science (New York, N.Y.) 2008;321(5897):1801-6.
2008: Daniel Laheru; Gary Croghan; Ronald Bukowski; MICHELLE RUDEK-RENAUT; Wells A Messersmith; Charles Erlichman; Robert Pelley; Antonio Jimeno; Ross C Donehower; Joseph Boni; Richat Abbas; Patricia Martins; Charles Zacharchuk; Manuel Hidalgo
A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(17):5602-9.
2008: Antonio Jimeno; MICHELLE RUDEK-RENAUT; Peter Kulesza; Wen W Ma; Jenna Wheelhouse; Anna Howard; Yasmin Khan; Ming Zhao; Heather A Jacene; Wells A Messersmith; Daniel Laheru; Ross C Donehower; Elizabeth Garrett-Mayer; Sharyn D Baker; Manuel Hidalgo
Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(25):4172-9.
2008: JOSEPH HERMAN; Michael J Swartz; Charles C Hsu; Jordan Winter; Timothy M Pawlik; Elizabeth Sugar; Ray Robinson; Daniel Laheru; Elizabeth M Jaffee; Ralph Hruban; Kurtis A Campbell; Christopher L Wolfgang; Fariba Asrari; Ross C Donehower; Manuel Hidalgo; Luis Alberto Diaz; Charles Yeo; John L Cameron; Richard D Schulick; Ross Abrams
Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(21):3503-10.
2008: Manuel Hidalgo; M E Saez; F J Martinez-Tello; F J Moron; E Ferrero-Herrero; M Labalde-Martinez; D Rigopoulou; C Ballestin-Carcavilla; A Ruiz; J L Royo; R Ramirez-Lorca
Absence of allelic imbalance involving EMSY, CAPN5, and PAK1 genes in papillary thyroid carcinoma.
Journal of endocrinological investigation 2008;31(7):618-23.
2008: Noriyuki Omura; Chung-Pin Li; Ang Li; Seung-Mo Hong; Kim Walter; Antonio Jimeno; Manuel Hidalgo; Michael Goggins
Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma.
Cancer biology & therapy 2008;7(7):1146-56.
2008: Ming Zhao; Ping He; Linping Xu; Manuel Hidalgo; Daniel Laheru; MICHELLE RUDEK-RENAUT
Determination of salirasib (S-trans,trans-farnesylthiosalicylic acid) in human plasma using liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2008;869(1-2):142-5.
2008: Antonio Jimeno; Aik Choon Tan; Jordy Coffa; RAJESH KUMAR NV; Piotr Kulesza; Belen Rubio-Viqueira; Jenna Wheelhouse; Begoña Diosdado; Wells A Messersmith; Christine A Iacobuzio-Donahue; Anirban Maitra; Marileila Varella-Garcia; Fred R Hirsch; Gerrit A Meijer; Manuel Hidalgo
Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer.
Cancer research 2008;68(8):2841-9.
2008: Vanesa Gregorc; Manuel Hidalgo; Anna Spreafico; George Cusatis; Vienna Ludovini; Roxann G Ingersoll; S Marsh; S M Steinberg; M G Viganò; D Ghio; Eugenio Villa; Alex Sparreboom; Sharyn D Baker
Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib.
Clinical pharmacology and therapeutics 2008;83(3):477-84.
2008: Antonio Jimeno; MICHELLE RUDEK-RENAUT; W. PURCELL; Daniel Laheru; Wells A Messersmith; Janet Dancey; Michael A Carducci; Sharyn D Baker; Manuel Hidalgo; Ross C Donehower
Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors.
Cancer chemotherapy and pharmacology 2008;61(3):423-33.
2008: Antonio Jimeno; Wells A Messersmith; Carlton K K Lee; Wen W Ma; Daniel Laheru; Ross C Donehower; Sharyn D Baker; Manuel Hidalgo
Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(2):374-9.
2008: Manuel Hidalgo
Clinical development of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors: what lessons have we learned?
Advances in experimental medicine and biology 2008;610():128-43.
2008: Manuel Hidalgo; Jose Jorge Galan; Carmen Sáez; Eduardo Ferrero; Carolina Castilla; Reposo Ramirez-Lorca; Pablo Pelaez; Agustin Ruiz; Miguel A Japón; Jose Luis Royo
Methylation alterations are not a major cause of PTTG1 misregulation.
BMC cancer 2008;8():110.
2007: Wen W Ma; Manuel Hidalgo
Exploiting novel molecular targets in gastrointestinal cancers.
World journal of gastroenterology : WJG 2007;13(44):5845-56.
2007: Kishan J Pandya; Suzanne Dahlberg; Manuel Hidalgo; Roger B Cohen; Martin W Lee; Joan H Schiller; David H Johnson
A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500).
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2007;2(11):1036-41.
2007: Jing Li; Ming Zhao; Antonio Jimeno; Ping He; M V Ramana Reddy; Manuel Hidalgo; Ross C Donehower; MICHELLE RUDEK-RENAUT
Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ON 01910.Na, a mitotic progression modulator, in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2007;856(1-2):198-204.
2007: Antonio Jimeno; Najat C Daw; Maria L Amador; George Cusatis; Piotr Kulesza; Mark Krailo; Ashish Ingle; Susan M Blaney; Peter Charles Adamson; Manuel Hidalgo
Analysis of biologic surrogate markers from a Children's Oncology Group Phase I trial of gefitinib in pediatric patients with solid tumors.
Pediatric blood & cancer 2007;49(3):352-7.
2007: Wells A Messersmith; Manuel Hidalgo
Panitumumab, a monoclonal anti epidermal growth factor receptor antibody in colorectal cancer: another one or the one?
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(16):4664-6.
2007: Shirin Khambata-Ford; Christopher R Garrett; Neal J Meropol; Mark Basik; Christopher T Harbison; Shujian Wu; Tze Wai Wong; Xin Huang; Chris H Takimoto; Andrew K Godwin; Benjamin R Tan; Smitha S Krishnamurthi; Howard A Burris; Elizabeth A Poplin; Manuel Hidalgo; Jose Baselga; Edwin A Clark; David J Mauro
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(22):3230-7.
2007: Jing Li; Ming Zhao; Ping He; Manuel Hidalgo; Sharyn D Baker
Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(12):3731-7.
2007: Antonio Jimeno; Gurulingappa Hallur; Audrey Chan; Xiangfeng Zhang; George Cusatis; Fonda Chan; Preeti Shah; Rongbing Chen; Ernest Hamel; Elizabeth Garrett-Mayer; Saeed R Khan; Manuel Hidalgo
Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein tau is predictive of their activity in pancreatic cancer.
Molecular cancer therapeutics 2007;6(5):1509-16.
2007: E Calvo; Shazli N Malik; Lillian L Siu; G M Baillargeon; J Irish; Soo F Chin; P Santabarbara; Jeffrey I Kreisberg; Eric K Rowinsky; Manuel Hidalgo
Assessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(4):761-7.
2007: Antonio Jimeno; Piotr Kulesza; J Wheelhouse; A Chan; X Zhang; Erik Kincaid; R Chen; Douglas P Clark; Arlene A Forastiere; Manuel Hidalgo
Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy.
British journal of cancer 2007;96(6):952-9.
2007: Antonio Jimeno; Belen Rubio-Viqueira; Maria L Amador; Victor Grunwald; Anirban Maitra; Christine A Iacobuzio-Donahue; Manuel Hidalgo
Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer.
Molecular cancer therapeutics 2007;6(3):1079-88.
2007: Jing Li; George Cusatis; Julie R Brahmer; Alex Sparreboom; Robert W Robey; Susan E Bates; Manuel Hidalgo; Sharyn D Baker
Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients.
Cancer biology & therapy 2007;6(3):432-8.
2007: Manuel Hidalgo
The Development of rapamycin as an orphan drug.
Clinical advances in hematology & oncology : H&O 2007;5(2):99-100.
2007: Belen Rubio-Viqueira; Heather Mezzadra; Matthew Nielsen; Antonio Jimeno; Xianfeng Zhang; Christine A Iacobuzio-Donahue; Anirban Maitra; Manuel Hidalgo; Soner Altiok
Optimizing the development of targeted agents in pancreatic cancer: tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays.
Molecular cancer therapeutics 2007;6(2):515-23.
2007: Ming Zhao; MICHELLE RUDEK-RENAUT; Ping He; Frank-Thorsten Hafner; Martin Radtke; John J Wright; B Douglas Smith; Wells A Messersmith; Manuel Hidalgo; Sharyn D Baker
A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2007;846(1-2):1-7.
2007: SANJAY GOEL; Manuel Hidalgo; Roman Perez-Soler
EGFR inhibitor-mediated apoptosis in solid tumors.
Journal of experimental therapeutics & oncology 2007;6(4):305-20.
2007: Jose Luis Royo; Manuel Hidalgo; Agustin Ruiz
Pyrosequencing protocol using a universal biotinylated primer for mutation detection and SNP genotyping.
Nature protocols 2007;2(7):1734-9.
2006: Amita Patnaik; Debra Wood; Anthony W Tolcher; Marta Hamilton; Jeffrey I Kreisberg; Lisa A Hammond; Garry Schwartz; Muralidhar Beeram; Manuel Hidalgo; Monica Mita; Julie Wolf; Paul Nadler; Eric K Rowinsky
Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(24):7406-13.
2006: George Cusatis; Vanesa Gregorc; Jing Li; Anna Spreafico; Roxann G Ingersoll; Jaap Verweij; Vienna Ludovini; Eugenio Villa; Manuel Hidalgo; Alex Sparreboom; Sharyn D Baker
Pharmacogenetics of ABCG2 and adverse reactions to gefitinib.
Journal of the National Cancer Institute 2006;98(23):1739-42.
2006: Jing Li; Mats O Karlsson; Julie R Brahmer; Avery Spitz; Ming Zhao; Manuel Hidalgo; Sharyn D Baker
CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors.
Journal of the National Cancer Institute 2006;98(23):1714-23.
2006: Antonio Jimeno; Maria L Amador; Piotr Kulesza; Xiaofei Wang; Belen Rubio-Viqueira; Xiangfeng Zhang; Audrey Chan; Jenna Wheelhouse; Hidekazu Kuramochi; Koji Tanaka; Kathleen Danenberg; Wells A Messersmith; Virna Almuete; Ralph Hruban; Anirban Maitra; Charles J Yeo; Manuel Hidalgo
Assessment of celecoxib pharmacodynamics in pancreatic cancer.
Molecular cancer therapeutics 2006;5(12):3240-7.
2006: Antonio Jimeno; Manuel Hidalgo
Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.
Biochimica et biophysica acta 2006;1766(2):217-29.
2006: Wells A Messersmith; Manuel Hidalgo; Michael A Carducci; S Gail Eckhardt
Novel targets in solid tumors: MEK inhibitors.
Clinical advances in hematology & oncology : H&O 2006;4(11):831-6.
2006: Antoinette R Tan; Dirk Moore; Manuel Hidalgo; James Doroshow; Elizabeth Poplin; Susan Goodin; David J Mauro; Eric H Rubin
Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(21):6517-22.
2006: Manuel Hidalgo; Jan C Buckner; Charles Erlichman; Marilyn S Pollack; Joseph P Boni; Gary Dukart; Bonnie Marshall; Lisa Speicher; Laurence Moore; Eric K Rowinsky
A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(19):5755-63.
2006: Ricardo Hitt; Patricia Martín; Manuel Hidalgo
Cetuximab in squamous cell carcinoma of the head and neck.
Future oncology (London, England) 2006;2(4):449-57.
2006: Belen Rubio-Viqueira; Antonio Jimeno; George Cusatis; Xianfeng Zhang; Christine A Iacobuzio-Donahue; Collins A Karikari; Chanjuan Shi; Kathleen Danenberg; Peter V Danenberg; Hidekazu Kuramochi; Koji Tanaka; Sharat Singh; Hossein Salimi-Moosavi; Nadia Bouraoud; Maria L Amador; Soner Altiok; Piotr Kulesza; Charles Yeo; Wells A Messersmith; James R Eshleman; Ralph Hruban; Anirban Maitra; Manuel Hidalgo
An in vivo platform for translational drug development in pancreatic cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(15):4652-61.
2006: Antonio Jimeno; Manuel Hidalgo
Multitargeted therapy: can promiscuity be praised in an era of political correctness?
Critical reviews in oncology/hematology 2006;59(2):150-8.
2006: Linda L Garland; Manuel Hidalgo; David S Mendelson; David P Ryan; Banu Arun; Jennifer L Lovalvo; Irene A Eiseman; Stephen C Olson; Peter F Lenehan; Joseph P Eder
A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(14 Pt 1):4274-82.
2006: Manuel Hidalgo; Maria L Amador; Antonio Jimeno; Heather Mezzadra; Pina Patel; Audrey Chan; Matthew Nielsen; Anirban Maitra; Soner Altiok
Assessment of gefitinib- and CI-1040-mediated changes in epidermal growth factor receptor signaling in HuCCT-1 human cholangiocarcinoma by serial fine needle aspiration.
Molecular cancer therapeutics 2006;5(7):1895-903.
2006: Jing Li; Julie R Brahmer; Wells A Messersmith; Manuel Hidalgo; Sharyn D Baker
Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients.
Investigational new drugs 2006;24(4):291-7.
2006: Belen Rubio-Viqueira; Manuel Hidalgo
Targeting mTOR for cancer treatment.
Current opinion in investigational drugs (London, England : 2000) 2006;7(6):501-12.
2006: Charles Erlichman; Manuel Hidalgo; Joseph P Boni; Patricia Martins; Susan E Quinn; Charles Zacharchuk; Peter Amorusi; Alex A. Adjei; Eric K Rowinsky
Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(15):2252-60.
2006: Valeria Sebastiani; Francesca Ricci; Belen Rubio-Viqueira; Belen Rubio-Viquiera; Piotr Kulesza; Charles J Yeo; Manuel Hidalgo; Alison P Klein; Daniel Laheru; Christine A Iacobuzio-Donahue
Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(8):2492-7.
2006: Gurulingappa Hallur; Antonio Jimeno; Susan L Dalrymple; Tao Zhu; M Katherine Jung; Manuel Hidalgo; John T Isaacs; Saraswati Sukumar; Ernest Hamel; Saeed R Khan
Benzoylphenylurea sulfur analogues with potent antitumor activity.
Journal of medicinal chemistry 2006;49(7):2357-60.
2006: Antonio Jimeno; Manuel Hidalgo
Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer.
Molecular cancer therapeutics 2006;5(4):787-96.
2006: Carlton K K Lee; Eric K Rowinsky; Jing Li; Francis Giles; Malcolm J Moore; Manuel Hidalgo; Edmund Capparelli; Jacques Jolivet; Sharyn D Baker
Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(7 Pt 1):2158-65.
2006: Antonio Jimeno; Piotr Kulesza; Erik Kincaid; Nadia Bouaroud; Audrey Chan; Arlene A Forastiere; Julie R Brahmer; Douglas P Clark; Manuel Hidalgo
C-fos assessment as a marker of anti-epidermal growth factor receptor effect.
Cancer research 2006;66(4):2385-90.
2006: Belen Rubio-Viqueira; Manuel Hidalgo
Targeting mTOR for cancer treatment.
Advances in experimental medicine and biology 2006;587():309-27.
2005: Collins A Karikari; Michael Mullendore; James R Eshleman; Pedram Argani; Lorenzo Leoni; Shrikanta Chattopadhyay; Manuel Hidalgo; Anirban Maitra
Homozygous deletions of methylthioadenosine phosphorylase in human biliary tract cancers.
Molecular cancer therapeutics 2005;4(12):1860-6.
2005: MICHELLE RUDEK-RENAUT; Ming Zhao; Nicola F Smith; Robert W Robey; Ping He; Gurulingappa Hallur; Saeed R Khan; Manuel Hidalgo; Antonio Jimeno; A Dimitrios Colevas; Wells A Messersmith; Antonio C Wolff; Sharyn D Baker
In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(23):8503-11.
2005: Wells A Messersmith; Darin Oppenheimer; Josep Peralba; Valeria Sebastiani; Maria Amador; Antonio Jimeno; Erlinda Embuscado; Manuel Hidalgo; Christine A Iacobuzio-Donahue
Assessment of Epidermal Growth Factor Receptor (EGFR) signaling in paired colorectal cancer and normal colon tissue samples using computer-aided immunohistochemical analysis.
Cancer biology & therapy 2005;4(12):1381-6.
2005: Manuel Hidalgo; M J Castillo; J L Eymar; A Hidalgo
Lichtenstein inguinal hernioplasty: sutures versus glue.
Hernia : the journal of hernias and abdominal wall surgery 2005;9(3):242-4.
2005: Carlos Gómez-Martín; Belen Rubio-Viqueira; Manuel Hidalgo
Current status of mammalian target of rapamycin inhibitors in lung cancer.
Clinical lung cancer 2005;7 Suppl 1():S13-8.
2005: Alex A. Adjei; Manuel Hidalgo
Treating cancer by blocking cell signals.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(23):5279-80.
2005: Evanthia C Galanis; Jan C Buckner; Matthew J Maurer; Jeffrey I Kreisberg; Karla V Ballman; Joseph P Boni; Josep M Peralba; Robert B Jenkins; Shaker R Dakhil; Roscoe F Morton; Kurt A Jaeckle; Bernd W Scheithauer; Janet Dancey; Manuel Hidalgo; Daniel J Walsh
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(23):5294-304.
2005: Alex A. Adjei; Manuel Hidalgo
Intracellular signal transduction pathway proteins as targets for cancer therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(23):5386-403.
2005: Antonio Jimeno; Manuel Hidalgo
Promises and pitfalls in the prediction of antiepidermal growth factor receptor activity.
Expert review of anticancer therapy 2005;5(4):727-35.
2005: José L Porrero; Carlos Sánchez-Cabezudo; Oscar Bonachía; Adolfo López-Buenadicha; Alfonso Sanjuánbenito; Manuel Hidalgo
[Inguinofemoral hernia: multicenter study of surgical techniques].
Cirugía española 2005;78(1):45-9.
2005: Ming Zhao; Carol Hartke; Antonio Jimeno; Jing Li; Ping He; Yelena Zabelina; Manuel Hidalgo; Sharyn D Baker
Specific method for determination of gefitinib in human plasma, mouse plasma and tissues using high performance liquid chromatography coupled to tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2005;819(1):73-80.
2005: Erlinda E Embuscado; Daniel Laheru; Francesca Ricci; Ki Jung Yun; Sten de Boom Witzel; Allison Seigel; Katie Flickinger; Manuel Hidalgo; G Steven Bova; Christine A Iacobuzio-Donahue
Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy.
Cancer biology & therapy 2005;4(5):548-54.
2005: Antonio Jimeno; Belen Rubio-Viqueira; Maria L Amador; Darin Oppenheimer; Nadia Bouraoud; Piotr Kulesza; Valeria Sebastiani; Anirban Maitra; Manuel Hidalgo
Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents.
Cancer research 2005;65(8):3003-10.
2005: Srinivas K Kumar; Maria Amador; Manuel Hidalgo; Sujata V Bhat; Saeed R Khan
Design, synthesis and biological evaluation of novel riccardiphenol analogs.
Bioorganic & medicinal chemistry 2005;13(8):2873-80.
2005: Antonio Jimeno; Manuel Hidalgo
Blockade of epidermal growth factor receptor (EGFR) activity.
Critical reviews in oncology/hematology 2005;53(3):179-92.
2005: Michael Burczynski; Natalie C Twine; Gary Dukart; Bonnie Marshall; Manuel Hidalgo; Walter M Stadler; Theodore Logan; Janice Dutcher; Gary R Hudes; William L Trepicchio; Andrew Strahs; Fred Immermann; Donna K Slonim; Andrew J Dorner
Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(3):1181-9.
2005: Xiaoping Xu; Yao Wang; Zhihua Chen; Mark D Sternlicht; Manuel Hidalgo; Bjorn Steffensen
Matrix metalloproteinase-2 contributes to cancer cell migration on collagen.
Cancer research 2005;65(1):130-6.
2004: Maria L Amador; Darin Oppenheimer; Sofia Perea; Anirban Maitra; George Cusatis; George Cusati; Christine A Iacobuzio-Donahue; Sharyn D Baker; Raheela Ashfaq; Chris Takimoto; Arlene A Forastiere; Manuel Hidalgo
An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors.
Cancer research 2004;64(24):9139-43.
2004: Sofia Perea; Manuel Hidalgo
Predictors of sensitivity and resistance to epidermal growth factor receptor inhibitors.
Clinical lung cancer 2004;6 Suppl 1():S30-4.
2004: Linda A de Graffenried; William E Friedrichs; Douglas H Russell; Elissa J Donzis; Amanda K Middleton; Jessica M Silva; Richard A Roth; Manuel Hidalgo
Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(23):8059-67.
2004: David Goldenberg; Eli Rosenbaum; Pedram Argani; Ignacio I Wistuba; David Sidransky; Paul J Thuluvath; Manuel Hidalgo; Joseph A Califano; Anirban Maitra
The V599E BRAF mutation is uncommon in biliary tract cancers.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2004;17(11):1386-91.
2004: Wells A Messersmith; Daniel Laheru; Neil Senzer; Ross C Donehower; Paula Grouleff; Theresa Rogers; Sean K Kelley; David A Ramies; Bert L Lum; Manuel Hidalgo
Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(19):6522-7.
2004: Samira Syed; Chris H Takimoto; Manuel Hidalgo; Jinee Rizzo; John Kuhn; Lisa A Hammond; Garry Schwartz; Anthony W Tolcher; Amita Patnaik; S Gail Eckhardt; Eric K Rowinsky
A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(19):6512-21.
2004: Jens Koopmann; Paul J Thuluvath; Marianna Zahurak; Troels Zakarias Kristiansen; Akhilesh Pandey; Richard D Schulick; Pedram Argani; Manuel Hidalgo; Stefano Iacobelli; Michael Goggins; Anirban Maitra
Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma.
Cancer 2004;101(7):1609-15.
2004: Linda A de Graffenried; Letitia Fulcher; William E Friedrichs; Viktor Grünwald; Ratna B Ray; Manuel Hidalgo
Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(10):1510-6.
2004: Manuel Hidalgo
New target, new drug, old paradigm.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(12):2270-2.
2004: Linda A de Graffenried; Bysani Chandrasekar; William E Friedrichs; E Donzis; J Silva; Manuel Hidalgo; James W Freeman; G R Weiss
NF-kappa B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(6):885-90.
2004: Hallur Gurulingappa; Maria L Amador; Ming Zhao; MICHELLE RUDEK-RENAUT; Manuel Hidalgo; Saeed R Khan
Synthesis and antitumor evaluation of benzoylphenylurea analogs.
Bioorganic & medicinal chemistry letters 2004;14(9):2213-6.
2004: Maria L Amador; Manuel Hidalgo
Epidermal growth factor receptor as a therapeutic target for the treatment of colorectal cancer.
Clinical colorectal cancer 2004;4(1):51-62.
2004: Michael B Atkins; Manuel Hidalgo; Walter M Stadler; Theodore F Logan; Janice P Dutcher; Gary R Hudes; Young Park; Song-Heng Liou; Bonnie Marshall; Joseph P Boni; Gary Dukart; Matthew L Sherman
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):909-18.
2004: José L Porrero; Manuel Hidalgo; Alfonso Sanjuanbenito; C Sanchez-Cabezudo
The Shouldice herniorrhaphy in the treatment of inguinal hernias: a prospective study on 775 patients.
Hernia : the journal of hernias and abdominal wall surgery 2004;8(1):60-3.
2004: Hetty Carraway; Manuel Hidalgo
New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists.
Breast cancer research : BCR 2004;6(5):219-24.
2004: Denis Soulieres; Neil Senzer; Everett E Vokes; Manuel Hidalgo; Sanjiv S Agarwala; Lillian L Siu
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(1):77-85.
2003: Manuel Hidalgo
Erlotinib: preclinical investigations.
Oncology (Williston Park, N.Y.) 2003;17(11 Suppl 12):11-6.
2003: Maria L Amador; J Jimeno; Luis Paz-Ares; Hernán Cortes-Funes; Manuel Hidalgo
Progress in the development and acquisition of anticancer agents from marine sources.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(11):1607-15.
2003: Natalie C Twine; Jennifer A Stover; Bonnie Marshall; Gary Dukart; Manuel Hidalgo; Walter Stadler; Theodore Logan; Janice Dutcher; Gary R Hudes; Andrew J Dorner; Donna K Slonim; William L Trepicchio; Michael Burczynski
Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma.
Cancer research 2003;63(18):6069-75.
2003: Ming Zhao; Ping He; MICHELLE RUDEK-RENAUT; Manuel Hidalgo; Sharyn D Baker
Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2003;793(2):413-20.
2003: Josep Maria Peralba; Linda A de Graffenried; William E Friedrichs; Letitia Fulcher; Viktor Grünwald; Geoffrey Weiss; Manuel Hidalgo
Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(8):2887-92.
2003: Shazli N Malik; Lillian L Siu; Eric K Rowinsky; Linda A de Graffenried; Lisa A Hammond; Jinee Rizzo; Sarah S Bacus; Michael G Brattain; Jeffrey I Kreisberg; Manuel Hidalgo
Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(7):2478-86.
2003: Linda A de Graffenried; William E Friedrichs; Letitia Fulcher; Gabriel Fernandes; J M Silva; J-M Peralba; Manuel Hidalgo
Eicosapentaenoic acid restores tamoxifen sensitivity in breast cancer cells with high Akt activity.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(7):1051-6.
2003: Donna E Hansel; Ayman Rahman; Manuel Hidalgo; Paul J Thuluvath; Keith D Lillemoe; Richard Shulick; Ja-Lok Ku; Jae-Gahb Park; Kohje Miyazaki; Raheela Ashfaq; Ignacio I Wistuba; Ram Varma; Lesleyann Hawthorne; Joseph Geradts; Pedram Argani; Anirban Maitra
Identification of novel cellular targets in biliary tract cancers using global gene expression technology.
The American journal of pathology 2003;163(1):217-29.
2003: Viktor Grünwald; Manuel Hidalgo
Developing inhibitors of the epidermal growth factor receptor for cancer treatment.
Journal of the National Cancer Institute 2003;95(12):851-67.
2003: Manuel Hidalgo; Duane Bloedow
Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of Erlotinib (Tarceva).
Seminars in oncology 2003;30(3 Suppl 7):25-33.
2003: Viktor Grünwald; Manuel Hidalgo
Development of the epidermal growth factor receptor inhibitor OSI-774.
Seminars in oncology 2003;30(3 Suppl 6):23-31.
2003: Wells A Messersmith; Daniel Laheru; Manuel Hidalgo
Recent advances in the pharmacological treatment of colorectal cancer.
Expert opinion on investigational drugs 2003;12(3):423-34.
2003: Viktor Grünwald; Manuel Hidalgo
Development of the epidermal growth factor receptor inhibitor Tarceva (OSI-774).
Advances in experimental medicine and biology 2003;532():235-46.
2003: Shazli N Malik; Roble Bedolla; Manuel Hidalgo; Michael G Brattain; Jeffrey I Kreisberg
Immunohistochemical determination of EGFR-tyrosine kinase inhibition in clinical samples.
Methods in molecular medicine 2003;85():135-40.
2002: Scott E Kern; Ralph Hruban; Manuel Hidalgo; Charles J Yeo
An introduction to pancreatic adenocarcinoma genetics, pathology and therapy.
Cancer biology & therapy 2002;1(6):607-13.
2002: Viktor Grünwald; Linda A de Graffenried; Douglas Russel; William E Friedrichs; Ratna B Ray; Manuel Hidalgo
Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.
Cancer research 2002;62(21):6141-5.
2002: W. PURCELL; MICHELLE RUDEK-RENAUT; Manuel Hidalgo
Development of matrix metalloproteinase inhibitors in cancer therapy.
Hematology/oncology clinics of North America 2002;16(5):1189-227.
2002: Desirée Hao; Manuel Hidalgo
Promising developments in targeted therapies for non-small-cell lung cancer.
Clinical lung cancer 2002;4(2):111-23.
2002: Theresa Pluth Yeo; Ralph Hruban; Steven D Leach; Robb E Wilentz; Taylor A Sohn; Scott E Kern; Christine A Iacobuzio-Donahue; Anirban Maitra; Michael Goggins; Marcia Canto; Ross A. Abrams; Daniel Laheru; Elizabeth M Jaffee; Manuel Hidalgo; Charles J Yeo
Pancreatic cancer.
Current problems in cancer 2002;26(4):176-275.
2002: Lillian L Siu; Eric K Rowinsky; Lisa A Hammond; Geoffrey R Weiss; Manuel Hidalgo; Gary M Clark; Judy Moczygemba; Les Choi; Ron Linnartz; Nicholas C Barbet; Ivo Sklenar; Renaud Capdeville; Gregory Gan; Carl W Porter; Daniel Von Hoff; S Gail Eckhardt
A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2157-66.
2002: Viktor Grünwald; Manuel Hidalgo
The epidermal growth factor receptor: a new target for anticancer therapy.
Current problems in cancer 2002;26(3):109-64.
2002: Roy S Herbst; Manuel Hidalgo; A Scott Pierson; Scott N Holden; Michael Bergen; S Gail Eckhardt
Angiogenesis inhibitors in clinical development for lung cancer.
Seminars in oncology 2002;29(1 Suppl 4):66-77.
2002: Anthony J Murgo; Janet E Dancey; S Gail Eckhardt; Manuel Hidalgo; Arbuck Susan; Kenn Zerivitz; Barbara A Blaylock
New targets for cancer chemotherapy.
Cancer chemotherapy and biological response modifiers 2002;20():239-72.
2002: Miguel A Villalona-Calero; S Gail Eckhardt; Geoffrey Weiss; Manuel Hidalgo; Jos H Beijnen; Charlotte van Kesteren; Hilde Rosing; Elizabeth Campbell; Maura Kraynak; Luis Lopez-Lazaro; Cecilia Guzman; Daniel Von Hoff; José Jimeno; Eric K Rowinsky
A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(1):75-85.
2002: Johann S de Bono; Joseph Stephenson; Sharyn D Baker; Manuel Hidalgo; Amita Patnaik; Lisa A Hammond; Geoffrey Weiss; Andrew Goetz; Lillian Siu; Cecilia Simmons; Jacques Jolivet; Eric K Rowinsky
Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(1):96-109.
2001: R Gómez; Manuel Hidalgo; E Marques; L Marin; C Loinaz; I Gonzalez; I Garcia; E Moreno
Incidence and predisposing factors for incisional hernia in patients with liver transplantation.
Hernia : the journal of hernias and abdominal wall surgery 2001;5(4):172-6.
2001: Manuel Hidalgo; Lillian L Siu; J Nemunaitis; Jinee Rizzo; Lisa A Hammond; Chris H Takimoto; S Gail Eckhardt; Anthony W Tolcher; Carolyn D Britten; Louis Denis; K Ferrante; Daniel Von Hoff; S Silberman; Eric K Rowinsky
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(13):3267-79.
2001: Anthony W Tolcher; S Gail Eckhardt; John Kuhn; L Hammond; Geoffrey Weiss; Jinee Rizzo; Cheryl Aylesworth; Manuel Hidalgo; Amita Patnaik; Garry Schwartz; Sally A Felton; Elizabeth Campbell; Eric K Rowinsky
Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(11):2937-47.
2001: Manuel Hidalgo; Cheryl Aylesworth; Lisa A Hammond; Carolyn D Britten; Geoffrey Weiss; Joseph Stephenson; Garry Schwartz; Amita Patnaik; Lon Smith; Kathleen Molpus; Sally A Felton; E Gupta; K J Ferrante; A Tortora; Daryl Sonnichsen; J Skillings; Eric K Rowinsky
Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(9):2493-503.
2001: Manuel Hidalgo; S G Eckhardt
Matrix metalloproteinase inhibitors: how can we optimize their development?
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(3):285-7.
2001: Manuel Hidalgo; S Gail Eckhardt
Development of matrix metalloproteinase inhibitors in cancer therapy.
Journal of the National Cancer Institute 2001;93(3):178-93.
2001: Manuel Hidalgo; A Scott Pierson; S N Holden; M Bergen; S Gail Eckhardt
Therapeutic angiogenesis inhibitors in the treatment of cancer.
Advances in internal medicine 2001;47():159-90.
2000: Manuel Hidalgo; Eric K Rowinsky
The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.
Oncogene 2000;19(56):6680-6.
2000: S Gail Eckhardt; Sharyn D Baker; Carolyn D Britten; Manuel Hidalgo; Lillian Siu; Lisa A Hammond; Miguel A Villalona-Calero; Sally A Felton; Ronald L Drengler; John Kuhn; Gary M Clark; S L Smith; John R MacDonald; C Smith; Judy Moczygemba; Steven D Weitman; Daniel Von Hoff; Eric K Rowinsky
Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(24):4086-97.
2000: Amita Patnaik; Eric K Rowinsky; B K Tammara; Manuel Hidalgo; Ronald L Drengler; A M Garner; Lillian L Siu; Lisa A Hammond; Sally A Felton; S Mallikaarjun; Daniel Von Hoff; S Gail Eckhardt
Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(23):3974-85.
2000: C Gomez-Martin; C Solá; Javier Hornedo; Sofia Perea; Carlos Lumbreras; Vicente Valentí; Alberto Arcediano; M Rodriguez; R Salazar; Hernán Cortés-Funes; Manuel Hidalgo
Rifampin does not improve the efficacy of quinolone antibacterial prophylaxis in neutropenic cancer patients: results of a randomized clinical trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(10):2126-34.
2000: Eric K Rowinsky; R Humphrey; Lisa A Hammond; Cheryl Aylesworth; Leslie Ann Smetzer; Manuel Hidalgo; M Morrow; Lon Smith; A Garner; J M Sorensen; Daniel Von Hoff; S Gail Eckhardt
Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(1):178-86.
2000: Manuel Hidalgo; Miguel A Villalona-Calero; S Gail Eckhardt; Ronald L Drengler; G Rodriguez; Lisa A Hammond; Sami Diab; Geoffrey Weiss; A M Garner; Elizabeth Campbell; K Davidson; A Louie; J D O'Neil; R von Borstel; Daniel Von Hoff; Eric K Rowinsky
Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(1):167-77.
1999: Manuel Hidalgo; Elzbieta Izbicka; S Gail Eckhardt; J R MacDonald; Cesario Cerna; Lionel Gomez; Eric K Rowinsky; Steven D Weitman; Daniel Von Hoff
Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S, against adult and pediatric human tumor colony-forming units.
Anti-cancer drugs 1999;10(9):837-44.
1999: Sofia Perea; Manuel Hidalgo; Alberto Arcediano; M J Ramos; C Gomez; Javier Hornedo; Carlos Lumbreras; Dolores Folgueira; Hernán Cortes-Funes; A Rodriguez-Noriega
Incidence and clinical impact of fluoroquinolone-resistant Escherichia coli in the faecal flora of cancer patients treated with high dose chemotherapy and ciprofloxacin prophylaxis.
The Journal of antimicrobial chemotherapy 1999;44(1):117-20.
1999: Manuel Hidalgo; David A Rinaldi; G Medina; T Griffin; J Turner; Daniel Von Hoff
A phase I trial of topical topitriol (calcitriol, 1,25-dihydroxyvitamin D3) to prevent chemotherapy-induced alopecia.
Anti-cancer drugs 1999;10(4):393-5.
1999: Manuel Hidalgo; Elzbieta Izbicka; Cesario Cerna; Lionel Gomez; Eric K Rowinsky; Steven D Weitman; Daniel Von Hoff
Comparative activity of the cyclopropylpyrroloindole compounds adozelesin, bizelesin and carzelesin in a human tumor colony-forming assay.
Anti-cancer drugs 1999;10(3):295-302.
1999: Manuel Hidalgo; Daniel Castellano; Luis Paz-Ares; Cristina Gravalos; M Diaz-Puente; Ricardo Hitt; S Alonso; Hernán Cortes-Funes
Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(2):585-92.
1999: Carolyn D Britten; L Hammond; Manuel Hidalgo; Mace L Rothenberg; A Sharma; Sunil Sharma; Lillian Siu; Miguel A Villalona-Calero; Geoffrey R Weiss
New anticancer agents.
Cancer chemotherapy and biological response modifiers 1999;18():178-209.
1999: Manuel Hidalgo; Javier Hornedo; Carlos Lumbreras; José M Trigo; ramon colomer; Sofia Perea; C Gómez; A Ruiz; Rocío García-Carbonero; Hernán Cortés-Funes
Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial.
Cancer 1999;85(1):213-9.
1998: Ricardo Hitt; Daniel Castellano; Manuel Hidalgo; Rocío García-Carbonero; M Peña; A Brandariz; Jose Millan; J J Alvarez Vincent; Hernán Cortés-Funes
Phase II trial of cisplatin and gemcitabine in advanced squamous-cell carcinoma of the head and neck.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(12):1347-9.
1998: Manuel Hidalgo; G Rodriguez; John Kuhn; T Brown; Geoffrey Weiss; J P MacGovren; Daniel Von Hoff; Eric K Rowinsky
A Phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(11):2763-70.
1998: Manuel Hidalgo; C Mendiola; J M López-Vega; Daniel Castellano; M Mendez; E Batiste-Alenton; M López-Brea; J Belon; J N Batista; Hernán Cortés-Funes
A multicenter randomized Phase II trial of granulocyte-colony stimulating factor-supported, platinum-based chemotherapy with flexible midcycle cisplatin administration in patients with advanced ovarian carcinoma. PSAMOMA Cooperative Group, Spain.
Cancer 1998;83(4):719-25.
1998: H Gómez; Manuel Hidalgo; L Casanova; ramon colomer; DL Pen; Jorge Otero; W Rodríguez; C Carracedo; Hernán Cortés-Funes; Carlos Vallejos
Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(6):2065-9.
1998: Daniel Castellano; Pilar Lianes; Luis Paz-Ares; Manuel Hidalgo; J A Guerra; C Gómez-Martín; H Gómez; J Calzas; Hernán Cortés-Funes
A phase II study of a novel gemcitabine plus cisplatin regimen administered every three weeks for advanced non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(4):457-9.
1998: MI Manzanera; Manuel Hidalgo; D Hernández; C Jiménez; P Rico; A Gimeno; Enrique Moreno-González
[Surgical treatment of hepatolithiasis. Presentation of a case].
Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva 1998;90(1):51-2.
1997: Ricardo Hitt; Luis Paz-Ares; Manuel Hidalgo; ramon colomer; A Brandariz; M Peña; JJ Alvarez Vicent; Javier Hornedo; Hernán Cortés-Funes
Phase I/II study of paclitaxel/cisplatin as first-line therapy for locally advanced head and neck cancer.
Seminars in oncology 1997;24(6 Suppl 19):S19-20-S19-24.
1997: E Wasserman; Manuel Hidalgo; Javier Hornedo; Hernán Cortés-Funes
Octreotide (SMS 201-995) for hematopoietic support-dependent high-dose chemotherapy (HSD-HDC)-related diarrhoea: dose finding study and evaluation of efficacy.
Bone marrow transplantation 1997;20(9):711-4.
1997: Rocío García-Carbonero; Manuel Hidalgo; Luis Paz-Ares; J Calzas; H Gómez; J A Guerra; Ricardo Hitt; Javier Hornedo; ramon colomer; Hernán Cortés-Funes
Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(10):3178-84.
1997: Manuel Hidalgo; Luis Paz-Ares; F Rivera; Pilar Lianes; G Huidobro; A Ruiz; M López-Brea; J Sanz-Ortiz; J López López; Hernán Cortés-Funes; Josep Tabernero
Mediastinal non-seminomatous germ cell tumours (MNSGCT) treated with cisplatin-based combination chemotherapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(6):555-9.
1997: Manuel Hidalgo; Javier Hornedo; Carlos Lumbreras; José M Trigo; C Gómez; Sofia Perea; A Ruiz; Ricardo Hitt; Hernán Cortés-Funes
Lack of ability of ciprofloxacin-rifampin prophylaxis to decrease infection-related morbidity in neutropenic patients given cytotoxic therapy and peripheral blood stem cell transplants.
Antimicrobial agents and chemotherapy 1997;41(5):1175-7.
1997: Ricardo Hitt; Javier Hornedo; ramon colomer; Manuel Hidalgo; A Brandariz; M Peña; J A Vicent; Hernán Cortés-Funes
Study of escalating doses of paclitaxel plus cisplatin in patients with inoperable head and neck cancer.
Seminars in oncology 1997;24(1 Suppl 2):S2-58-S2-64.
1996: Manuel Hidalgo; J Benito; ramon colomer; Luis Paz-Ares
Recall reaction of a severe local peripheral neuropathy after paclitaxel extravasation.
Journal of the National Cancer Institute 1996;88(18):1320.
1996: Manuel Hidalgo; Carlos Lumbreras; José María Aguado
[Lymphoproliferative syndromes associated to the Epstein Barr virus in organ transplants].
Medicina clínica 1996;107(8):310-6.
1996: MI Manzanera; Carmelo Loinaz; F López-Ríos; D Hernández; Carlos Jiménez; Ramón Gómez; P Rico; D R Rodríguez; C Castellón; Manuel Hidalgo; Enrique Moreno-González
[Endometriosis of the round ligament presenting as inguinal hernia].
Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva 1996;88(7):518-20.
1995: Ramón Gómez; Enrique Moreno; Carmelo Loinaz; Angel De-La-Calle; C Castellon; MI Manzanera; V Herrera; A Garcia; Manuel Hidalgo
Diaphragmatic or transdiaphragmatic thoracic involvement in hepatic hydatid disease: surgical trends and classification.
World journal of surgery 1995;19(5):714-9; discussion 719.
1992: Ramón Gómez; M Marcello; Enrique Moreno; D Hernández; A Calle; J Palomo; Carmelo Loinaz; G Trombatore; A Alvarado; Manuel Hidalgo
[Incidence and surgical treatment of extrahepatic abdominal hydatidosis].
Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva 1992;82(2):100-3.
1992: Ramón Gómez; J Seoane; D Moreno; B Cuenca; Manuel Hidalgo; A García; J C Palomo; M Marcello; Enrique Moreno
[Manometric changes induced by antireflux surgery (Nissen) and its relation to pH measurement and clinical findings. An analysis 6 months after the intervention].
Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva 1992;82(1):1-6.
1986: Manuel Hidalgo; Enrique Moreno; Carlos Jiménez; A Calle; P Rico; J Seoane; D Mansilla
[Sphincterotomy and sphincteroplasty: a comparative study in a series of 257 patients].
Revista española de las enfermedades del aparato digestivo 1986;70(2):95-106.